OriGene Tech raises $16M in venture cash; GW says it's finally on track for regulatory approval;

 @FierceBiotech: Biopharma R&D rises 2% in '09 despite recession. Report | Follow @FierceBiotech

 @JohnCFierce: Little Arca gets NASDAQ warning a week after going concern notice. A few months of cash in the bank. Needs to pay for a big trial. Gulp. | Follow @JohnCFierce

> OriGene Technologies has completed a $16 million Series B financing led by IDG-Accel, SBI & TH Venture Capital Enterprise, and Zero2IPO. The money will be used to continue to build OriGene's TrueMAB monoclonal antibody collection. OriGene release

> GW Pharmaceuticals says it's on track to gain regulatory approvals for its long-delayed cannabis therapy in Spain and Britain. An approval for Sativex would mark a major turning point for GW. Story

> Shares of the UK's Vectura took a hit this morning after the developer announced that it had agreed with its partner Novartis to take over U.S. development of an asthma drug-VR315--widely believed to be a copycat version of Glaxo's Advair. Story

> Theravance plans to sell 7.5 million shares. Story

> Antisoma says it has started a randomized Phase IIb trial of AS1411 in patients with acute myeloid leukaemia. Antisoma release

> Quintiles executives are offering up a new analysis of the Asia-Pacific drug development landscape and its evolution from outsourcing destination to potential pharmaceutical innovation hub of the future. Quintiles release

And Finally... Officials in China have begun an investigation into the deaths of four children after the China Economic Times reported the use of unsafe vaccines in Shanxi-the latest in a long series of pharma-related scandals. Report

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.